Work

Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.6_suppl.98

Authors: Atish Dipankar Choudhury, Lucia Kwak, Alexander Cheung, Abhishek Tripathi, Amanda Fredericks Pace, Eliezer Mendel Van Allen, Kerry L. Kilbridge, Xiao X. Wei, Bradley Alexander McGregor, Mark Pomerantz, Christopher Sweeney, Mary-Ellen Taplin, Heather Jacene, Glenn Bubley, Lauren C Harshman, Lawrence Fong, Rupal Satish Bhatt

Institutions: Dana-Farber Cancer Institute, University of California, San Francisco, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Beth Israel Deaconess Medical Center, UCSF Helen Diller Family Comprehensive Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Merck Sharp and Dohme

OpenAlex ID: W3135723205

Cites:

Cited by: 16

Related to: 10